Goodness Growth Holdings Subsidiary Resurgent Biosciences Launches First IRB-Approved Research Study on Entheogens & Psychedelic Experiences - Investing News Network

Goodness Growth Holdings, Inc. (“Goodness Growth” or the “Company”) (CSE: GDNS; OTCQX: GDNSF), a physician-led, science-focused cannabis company and IP incubator, today announced that its subsidiary, Resurgent Biosciences, Inc. (“Resurgent”), is actively recruiting 100 participants to take part in an anonymous online survey to research the varying effects of entheogen and psychedelic experiences for therapeutic, religious, or spiritual purposes. The research will help inform Resurgent on future developments including research and wellness applications designed to help promote more positive, long-lasting outcomes from psychedelic-based therapies.

Existing research into the therapeutic use of psychedelics has focused heavily on synthetic substances, such as LSD, Ketamine, and MDMA, performed in controlled clinical settings. The survey being conducted by Resurgent, which has received approval from an independent Institutional Review Board (“IRB”) registered with the Office for Human Research Protections (“OHRP”), will instead focus on the naturalistic use of entheogens and other substances typically used in specific cultural and spiritual contexts for healing.

“Entheogens” refers to traditional substances, more commonly referred to as psychedelics, of fully natural origin and ingested to impact one’s consciousness for therapeutic, religious, or spiritual purposes. This is an innovative, first-of-its-kind survey delving into some key questions surrounding entheogen usage.

“...



Read Full Story: https://investingnews.com/daily/cannabis-investing/goodness-growth-holdings-subsidiary-resurgent-biosciences-launches-first-irb-approved-research-study-on-entheogens-psychedelic-experiences/


Your content is great. However, if any of the content contained herein violates any rights of yours, including those of copyright, please contact us immediately by e-mail at media[@]kissrpr.com.


Tags: